Noradrenergic dysfunction in Alzheimer's disease

Frontiers in Neuroscience

Volumn 9, Issue JUN, 2015, Pages

  Gannon, Mary ^a   Che, Pulin ^a   Chen, Yunjia ^a   Jiao, Kai ^b   Roberson, Erik D ^c   Wang, Qin ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Adrenergic receptors; Degeneration; Dysfunction; Noradrenergic system; Norepinephrine

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ATIPAMEZOLE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CLONIDINE; EFAROXAN; NORADRENALIN; VESICULAR MONOAMINE TRANSPORTER;

ALZHEIMER DISEASE; AUTONOMIC NEUROPATHY; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; HUMAN; LATENT PERIOD; LOCUS CERULEUS; LONG TERM POTENTIATION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN UPTAKE; NORADRENERGIC SYSTEM; PATHOGENESIS; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; WORKING MEMORY;

EID: 84936862890     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00220     Document Type: Review

References (151)

1. Adunsky, A., Hershkowitz, M., and Rabinowitz, M. (1989). Alzheimer's dementia and binding to alpha 2 adrenoreceptors in platelets. J. Am. Geriatr. Soc. 37, 741-744. doi: 10.1111/j.1532-5415.1989.tb02236.x
2. Arnsten, A. F., Cai, J. X., and Goldman-Rakic, P. S. (1988). The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J. Neurosci. 8, 4287-4298.
3. Arnsten, A. F., and Goldman-Rakic, P. S. (1985). Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230, 1273-1276. doi: 10.1126/science.2999977
4. Arnsten, A. F., and Goldman-Rakic, P. S. (1987). Noradrenergic mechanisms in age-related cognitive decline. J. Neural Transm. Suppl. 24, 317-324.
5. Bennett, M. C., Kaleta-Michaels, S., Arnold, M., and Mcgaugh, J. L. (1990). Impairment of active avoidance by the noradrenergic neurotoxin, DSP4: attenuation by post-training epinephrine. Psychopharmacology 101, 505-510. doi: 10.1007/BF02244229
6. Bird, C. M., and Burgess, N. (2008). The hippocampus and memory: insights from spatial processing. Nat. Rev. Neurosci. 9, 182-194. doi: 10.1038/nrn2335
7. Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P., et al. (1987). Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1, 256-262. doi: 10.1097/00002093-198701040-00005
8. Braak, H., and Del Tredici, K. (2012). Where, when, and in what form does sporadic Alzheimer's disease begin? Curr. Opin. Neurol. 25, 708-714. doi: 10.1097/WCO.0b013e32835a3432
9. Branca, C., Wisely, E. V., Hartman, L. K., Caccamo, A., and Oddo, S. (2014). Administration of a selective beta2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol. Aging 35, 2726-2735. doi: 10.1016/j.neurobiolaging.2014.06.011
10. Brown, D. C. II, Co, M. S., Wolff, R. C., and Atzori, M. (2012). Alpha-Adrenergic receptors in auditory cue detection: alpha2 receptor blockade suppresses false alarm responding in the rat. Neuropharmacology 62, 2178-2183. doi: 10.1016/j.neuropharm.2011.12.024
11. Bullido, M. J., Ramos, M. C., Ruiz-Gomez, A., Tutor, A. S., Sastre, I., Frank, A., et al. (2004). Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's. Neurobiol. Aging 25, 853-859. doi: 10.1016/j.neurobiolaging.2003.10.006
12. Caglayan, S., Bauerfeind, A., Schmidt, V., Carlo, A. S., Prabakaran, T., Hubner, N., et al. (2012). Identification of Alzheimer disease risk genotype that predicts efficiency of SORL1 expression in the brain. Arch. Neurol. 69, 373-379. doi: 10.1001/archneurol.2011.788
13. Cai, J. X., Ma, Y. Y., Xu, L., and Hu, X. T. (1993). Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha 2-adrenergic agonist clonidine. Brain Res. 614, 191-196. doi: 10.1016/0006-8993(93)91034-P
14. Camacho, F., Smith, C. P., Vargas, H. M., and Winslow, J. T. (1996). Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 124, 347-354. doi: 10.1007/BF02247440
15. Chamberlain, S. R., and Robbins, T. W. (2013). Noradrenergic modulation of cognition: therapeutic implications. J. Psychopharmacol. 27, 694-718. doi: 10.1177/0269881113480988
16. Chen, Y., Peng, Y., Che, P., Gannon, M., Liu, Y., Li, L., et al. (2014). alpha(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc. Natl. Acad. Sci. U.S.A. 111, 17296-17301. doi: 10.1073/pnas.1409513111
17. Chen, Z. J., and Minneman, K. P. (2005). Recent progress in alpha1-adrenergic receptor research. Acta Pharmacol. Sin. 26, 1281-1287. doi: 10.1111/j.1745-7254.2005.00224.x
18. Chopin, P., Colpaert, F. C., and Marien, M. (2002). Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J. Pharmacol. Exp. Ther. 301, 187-196. doi: 10.1124/jpet.301.1.187
19. Combarros, O., Warden, D. R., Hammond, N., Cortina-Borja, M., Belbin, O., Lehmann, M. G., et al. (2010). The dopamine beta-hydroxylase-1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Med. Genet. 11, 162. doi: 10.1186/1471-2350-11-162
20. Cottingham, C., Chen, Y., Jiao, K., and Wang, Q. (2011). The antidepressant desipramine is an arrestin-biased ligand at the alpha(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo. J. Biol. Chem. 286, 36063-36075. doi: 10.1074/jbc.M111.261578
21. Cottingham, C., and Wang, Q. (2012). alpha2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy. Neurosci. Biobehav. Rev. 36, 2214-2225. doi: 10.1016/j.neubiorev.2012.07.011
22. Decker, M. W., Gill, T. M., and Mcgaugh, J. L. (1990). Concurrent muscarinic and beta-adrenergic blockade in rats impairs place-learning in a water maze and retention of inhibitory avoidance. Brain Res. 513, 81-85. doi: 10.1016/0006-8993(90)91091-T
23. Dobarro, M., Orejana, L., Aguirre, N., and Ramirez, M. J. (2013a). Propranolol reduces cognitive deficits, amyloid beta levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. Int. J. Neuropsychopharmacol. 16, 1351-1360. doi: 10.1017/S1461145712001393
24. Dobarro, M., Orejana, L., Aguirre, N., and Ramirez, M. J. (2013b). Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology 64, 137-144. doi: 10.1016/j.neuropharm.2012.06.047
25. Do Monte, F. H., Souza, R. R., Wong, T. T., and Carobrez, A. D. P. (2013). Systemic or intra-prelimbic cortex infusion of prazosin impairs fear memory reconsolidation. Behav. Brain Res. 244, 137-141. doi: 10.1016/j.bbr.2013.01.031
26. Doze, V. A., Papay, R. S., Goldenstein, B. L., Gupta, M. K., Collette, K. M., Nelson, B. W., et al. (2011). Long-term a1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol. Pharmacol. 80, 747-758. doi: 10.1124/mol.111.073734
27. Eimer, W. A., and Vassar, R. (2013). Neuron loss in the 5XFAD mouse model of Alzheimer;s disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol. Neurodegener. 8:2. doi: 10.1186/1750-1326-8-2
28. Elrod, R., Peskind, E. R., Digiacomo, L., Brodkin, K. I., Veith, R. C., and Raskind, M. A. (1997). Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am. J. Psychiatry 154, 25-30. doi: 10.1176/ajp.154.1.25
29. Forstl, H., Levy, R., Burns, A., Luthert, P., and Cairns, N. (1994). Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease - a hypothesis. Pharmacopsychiatry 27, 11-15. doi: 10.1055/s-2007-1014267
30. Franowicz, J. S., Kessler, L. E., Borja, C. M., Kobilka, B. K., Limbird, L. E., and Arnsten, A. F. (2002). Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 22, 8771-8777.
31. Gamache, K., Pitman, R. K., and Nader, K. (2012). Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder. Neuropsychopharmacology 37, 2789-2796. doi: 10.1038/npp.2012.145
32. Gamo, N. J., Wang, M., and Arnsten, A. F. (2010). Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J. Am. Acad. Child Adolesc. Psychiatry 49, 1011-1023. doi: 10.1016/j.jaac.2010.06.015
33. Gazarini, L., Stern, C. A., Carobrez, A. P., and Bertoglio, L. J. (2013). Enhanced noradrenergic activity potentiates fear memory consolidation and reconsolidation by differentially recruiting a1-and ß-adrenergic receptors. Learn. Mem. 20, 210-219. doi: 10.1101/lm.030007.112
34. Gelinas, J. N., Tenorio, G., Lemon, N., Abel, T., and Nguyen, P. V. (2008). ß-Adrenergic receptor activation during distinct patterns of stimulation critically modulates the PKA-dependence of LTP in the mouse hippocampus. Learn. Mem. 15, 281-289. doi: 10.1101/lm.829208
35. Gibbs, M. E., Maksel, D., Gibbs, Z., Hou, X., Summers, R. J., and Small, D. H. (2010). Memory loss caused by beta-amyloid protein is rescued by a beta(3)-adrenoceptor agonist. Neurobiol. Aging 31, 614-624. doi: 10.1016/j.neurobiolaging.2008.05.018
36. Giubilei, F., Calderaro, C., Antonini, G., Sepe-Monti, M., Tisei, P., Brunetti, E., et al. (2004). Increased lymphocyte dopamine beta-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit? Dement. Geriatr. Cogn. Disord. 18, 338-341. doi: 10.1159/000080128
37. Golan, D. E., Tashjian, A. H., and Armstrong, E. J. (2011). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Philadelphia, PA: Lippincott Williams & Wilkins.
38. Grear, K. E., Ling, I. F., Simpson, J. F., Furman, J. L., Simmons, C. R., Peterson, S. L., et al. (2009). Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol. Neurodegener. 4, 46. doi: 10.1186/1750-1326-4-46
39. Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., and Mesulam, M. M. (2007). Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging 28, 327-335. doi: 10.1016/j.neurobiolaging.2006.02.007
40. Guan, X., Blank, J. L., and Dluzen, D. E. (1993). Role of olfactory bulb norepinephrine in the identification and recognition of chemical cues. Physiol. Behav. 53, 437-441. doi: 10.1016/0031-9384(93)90136-4
41. Guerin, D., Sacquet, J., Mandairon, N., Jourdan, F., and Didier, A. (2009). Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. Neurobiol. Aging 30, 272-283. doi: 10.1016/j.neurobiolaging.2007.05.020
42. Gulyas, B., Brockschnieder, D., Nag, S., Pavlova, E., Kasa, P., Beliczai, Z., et al. (2010). The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: a post-mortem autoradiographic study. Neurochem. Int. 56, 789-798. doi: 10.1016/j.neuint.2010.03.001
43. Haapalinna, A., Sirvio, J., Macdonald, E., Virtanen, R., and Heinonen, E. (2000). The effects of a specific alpha(2)-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats. Eur. J. Pharmacol. 387, 141-150. doi: 10.1016/S0014-2999(99)00819-5
44. Hall, R. A. (2004). Beta-adrenergic receptors and their interacting proteins. Semin. Cell Dev. Biol. 15, 281-288. doi: 10.1016/j.semcdb.2003.12.017
45. Hammerschmidt, T., Kummer, M. P., Terwel, D., Martinez, A., Gorji, A., Pape, H. C., et al. (2013). Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol. Psychiatry 73, 454-463. doi: 10.1016/j.biopsych.2012.06.013
46. Hein, L. (2006). Adrenoceptors and signal transduction in neurons. Cell Tissue Res. 326, 541-551. doi: 10.1007/s00441-006-0285-2
47. Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., et al. (2010). Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U.S.A. 107, 6058-6063. doi: 10.1073/pnas.0909586107
48. Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., et al. (2006). Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343-1354. doi: 10.1523/JNEUROSCI.4236-05.2006
49. Hensley, K. (2010). Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J. Alzheimers Dis. 21, 1-14. doi: 10.3233/JAD-2010-1414
50. Herregodts, P., Bruyland, M., De Keyser, J., Solheid, C., Michotte, Y., and Ebinger, G. (1989). Monoaminergic neurotransmitters in Alzheimer's disease. An HPLC study comparing presenile familial and sporadic senile cases. J. Neurol. Sci. 92, 101-116. doi: 10.1016/0022-510X(89)90179-2
51. Hoogendijk, W. J., Feenstra, M. G., Botterblom, M. H., Gilhuis, J., Sommer, I. E., Kamphorst, W., et al. (1999). Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol. 45, 82-91.
52. Introini-Collison, I. B., Miyazaki, B., and Mcgaugh, J. L. (1991). Involvement of the amygdala in the memory-enhancing effects of clenbuterol. Psychopharmacology 104, 541-544. doi: 10.1007/BF02245663
53. Iversen, L. L., Rossor, M. N., Reynolds, G. P., Hills, R., Roth, M., Mountjoy, C. Q., et al. (1983). Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci. Lett. 39, 95-100. doi: 10.1016/0304-3940(83)90171-4
54. Jardanhazi-Kurutz, D., Kummer, M. P., Terwel, D., Vogel, K., Dyrks, T., Thiele, A., et al. (2010). Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem. Int. 57, 375-382. doi: 10.1016/j.neuint.2010.02.001
55. Jardanhazi-Kurutz, D., Kummer, M. P., Terwel, D., Vogel, K., Thiele, A., and Heneka, M. T. (2011). Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice. Neuroscience 176, 396-407. doi: 10.1016/j.neuroscience.2010.11.052
56. Jentsch, J. D., Aarde, S. M., and Seu, E. (2009). Effects of atomoxetine and methylphenidate on performance of a lateralized reaction time task in rats. Psychopharmacology 202, 497-504. doi: 10.1007/s00213-008-1181-0
57. Kalaria, R. N. (1989). Characterization of [125I]HEAT binding to alpha 1-receptors in human brain: assessment in aging and Alzheimer's disease. Brain Res. 501, 287-294. doi: 10.1016/0006-8993(89)90645-8
58. Kalaria, R. N., Andorn, A. C., Tabaton, M., Whitehouse, P. J., Harik, S. I., and Unnerstall, J. R. (1989a). Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J. Neurochem. 53, 1772-1781. doi: 10.1111/j.1471-4159.1989.tb09242.x
59. Kalaria, R. N., Stockmeier, C. A., and Harik, S. I. (1989b). Brain microvessels are innervated by locus ceruleus noradrenergic neurons. Neurosci. Lett. 97, 203-208. doi: 10.1016/0304-3940(89)90164-X
60. Kalinin, S., Gavrilyuk, V., Polak, P. E., Vasser, R., Zhao, J., Heneka, M. T., et al. (2007). Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 28, 1206-1214. doi: 10.1016/j.neurobiolaging.2006.06.003
61. Kalinin, S., Polak, P. E., Lin, S. X., Sakharkar, A. J., Pandey, S. C., and Feinstein, D. L. (2012). The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol. Aging 33, 1651-1663. doi: 10.1016/j.neurobiolaging.2011.04.012
62. Katsouri, L., Vizcaychipi, M. P., Mcarthur, S., Harrison, I., Suarez-Calvet, M., Lleo, A., et al. (2013). Prazosin, an alpha(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34, 1105-1115. doi: 10.1016/j.neurobiolaging.2012.09.010
63. Kenton, L., Boon, F., and Cain, D. P. (2008). Combined but not individual administration of beta-adrenergic and serotonergic antagonists impairs water maze acquisition in the rat. Neuropsychopharmacology 33, 1298-1311. doi: 10.1038/sj.npp.1301518
64. Khachaturian, A. S., Zandi, P. P., Lyketsos, C. G., Hayden, K. M., Skoog, I., Norton, M. C., et al. (2006). Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 63, 686-692. doi: 10.1001/archneur.63.5.noc60013
65. Knaus, A. E., Muthig, V., Schickinger, S., Moura, E., Beetz, N., Gilsbach, R., et al. (2007). Alpha2-adrenoceptor subtypes-unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem. Int. 51, 277-281. doi: 10.1016/j.neuint.2007.06.036
66. Komatsu, M., Shibata, N., Ohnuma, T., Kuerban, B., Tomson, K., Toda, A., et al. (2014). Polymorphisms in the aldehyde dehydrogenase 2 and dopamine beta hydroxylase genes are not associated with Alzheimer's disease. J. Neural. Transm. 121, 427-432. doi: 10.1007/s00702-013-1112-z
67. Kummer, M. P., Hammerschmidt, T., Martinez, A., Terwel, D., Eichele, G., Witten, A., et al. (2014). Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J. Neurosci. 34, 8845-8854. doi: 10.1523/JNEUROSCI.4027-13.2014
68. Lapiz, M. S., Mateo, Y., Durkin, S., Parker, T., and Marsden, C. A. (2001). Effects of central noradrenaline depletion by the selective neurotoxin DSP-4 on the behaviour of the isolated rat in the elevated plus maze and water maze. Psychopharmacology 155, 251-259. doi: 10.1007/s002130100702
69. Lemmer, B., Langer, L., Ohm, T., and Bohl, J. (1993). Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease. Naunyn Schmiedebergs. Arch. Pharmacol. 347, 214-219. doi: 10.1007/BF00169270
70. Levcik, D., Stuchlik, A., and Klement, D. (2013). Effect of block of a1-adrenoceptors on overall motor activity but not on spatial cognition in the object-position recognition task. Physiol. Res. 62, 561-567.
71. Leverenz, J. B., Miller, M. A., Dobie, D. J., Peskind, E. R., and Raskind, M. A. (2001). Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies. Neurobiol. Aging 22, 555-561. doi: 10.1016/S0197-4580(01)00221-4
72. Liu, Y., Yoo, M. J., Savonenko, A., Stirling, W., Price, D. L., Borchelt, D. R., et al. (2008). Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 28, 13805-13814. doi: 10.1523/JNEUROSCI.4218-08.2008
73. Lockrow, J., Boger, H., Gerhardt, G., Aston-Jones, G., Bachman, D., and Granholm, A.-C. (2011). A noradrenergic lesion exacerbates neurodegeneration in a down syndrome mouse model. J. Alzheimers Dis. 23, 471-489. doi: 10.3233/JAD-2010-101218
74. Mann, D. M. A., Lincoln, J., Yates, P. O., Stamp, J. E., and Toper, S. (1980). Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry 136, 533-541. doi: 10.1192/bjp.136.6.533
75. Marien, M. R., Colpaert, F. C., and Rosenquist, A. C. (2004). Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Rev. 45, 38-78. doi: 10.1016/j.brainresrev.2004.02.002
76. Marino, M. D., Bourdelat-Parks, B. N., Cameron Liles, L., and Weinshenker, D. (2005). Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice. Behav. Brain Res. 161, 197-203. doi: 10.1016/j.bbr.2005.02.005
77. Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G., and Nappi, G. (1992). Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect. 4, 191-205. doi: 10.1007/BF02260903
78. Matthews, K. L., Chen, C. P., Esiri, M. M., Keene, J., Minger, S. L., and Francis, P. T. (2002). Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry 51, 407-416. doi: 10.1016/S0006-3223(01)01235-5
79. Mishima, K., Tanoue, A., Tsuda, M., Hasebe, N., Fukue, Y., Egashira, N., et al. (2004). Characteristics of behavioral abnormalities in alpha1d-adrenoceptors deficient mice. Behav. Brain Res. 152, 365-373. doi: 10.1016/j.bbr.2003.10.038
80. Miyata, S., Nagata, H., Yamao, S., Nakamura, S., and Kameyama, M. (1984). Dopamine-beta-hydroxylase activities in serum and cerebrospinal fluid of aged and demented patients. J. Neurol. Sci. 63, 403-409. doi: 10.1016/0022-510X(84)90163-1
81. Nalepa, I., Kreiner, G., Bielawski, A., Rafa-Zablocka, K., and Roman, A. (2013). alpha1-Adrenergic receptor subtypes in the central nervous system: insights from genetically engineered mouse models. Pharmacol. Rep. 65, 1489-1497. doi: 10.1016/S1734-1140(13)71509-3
82. Nazarali, A. J., and Reynolds, G. P. (1992). Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell. Mol. Neurobiol. 12, 581-587. doi: 10.1007/BF00711237
83. Ni, Y., Zhao, X., Bao, G., Zou, L., Teng, L., Wang, Z., et al. (2006). Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat. Med. 12, 1390-1396. doi: 10.1038/nm1485
84. O'donnell, J., Zeppenfeld, D., Mcconnell, E., Pena, S., and Nedergaard, M. (2012). Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res. 37, 2496-2512. doi: 10.1007/s11064-012-0818-x
85. Ohno, M., Yoshimatsu, A., Kobayashi, M., and Watanabe, S. (1997). Noradrenergic DSP-4 lesions aggravate impairment of working memory produced by hippocampal muscarinic blockade in rats. Pharmacol.Biochem. Behav. 57, 257-261. doi: 10.1016/S0091-3057(96)00353-X
86. Oikawa, N., Ogino, K., Masumoto, T., Yamaguchi, H., and Yanagisawa, K. (2010). Gender effect on the accumulation of hyperphosphorylated tau in the brain of locus-ceruleus-injured APP-transgenic mouse. Neurosci. Lett. 468, 243-247. doi: 10.1016/j.neulet.2009.11.005
87. Ouyang, M., and Thomas, S. A. (2005). A requirement for memory retrieval during and after long-term extinction learning. Proc. Natl. Acad. Sci. U.S.A. 102, 9347-9352. doi: 10.1073/pnas.0502315102
88. Palmer, A. M., Francis, P. T., Bowen, D. M., Benton, J. S., Neary, D., Mann, D. M., et al. (1987). Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res. 414, 365-375. doi: 10.1016/0006-8993(87)90018-7
89. Pascual, J., Grijalba, B., Garcia-Sevilla, J. A., Zarranz, J. J., and Pazos, A. (1992). Loss of high-affinity alpha 2-adrenoceptors in Alzheimer's disease: an autoradiographic study in frontal cortex and hippocampus. Neurosci. Lett. 142, 36-40. doi: 10.1016/0304-3940(92)90614-D
90. Pauszek, M. E. (1991). Propranolol for treatment of agitation in senile dementia. Indiana Med. 84, 16-17.
91. Perez, D. M. (2007). Structure-function of alpha1-adrenergic receptors. Biochem. Pharmacol. 73, 1051-1062. doi: 10.1016/j.bcp.2006.09.010
92. Pérez, V., Marin, C., Rubio, A., Aguilar, E., Barbanoj, M., and Kulisevsky, J. (2009). Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances. J. Neural. Transm. 116, 1257-1266. doi: 10.1007/s00702-009-0291-0
93. Perry, G., Cash, A. D., and Smith, M. A. (2002). Alzheimer Disease and Oxidative Stress. J. Biomed. Biotechnol. 2, 120-123. doi: 10.1155/S1110724302203010
94. Peskind, E. R., Tsuang, D. W., Bonner, L. T., Pascualy, M., Riekse, R. G., Snowden, M. B., et al. (2005). Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis. Assoc. Disord. 19, 23-28. doi: 10.1097/01.wad.0000155067.16313.5e
95. Peskind, E. R., Wingerson, D., Murray, S., Pascualy, M., Dobie, D. J., Le Corre, P., et al. (1995). Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch. Gen. Psychiatry 52, 774-782. doi: 10.1001/archpsyc.1995.03950210068012
96. Philipp, M., and Hein, L. (2004). Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol. Ther. 101, 65-74. doi: 10.1016/j.pharmthera.2003.10.004
97. Pottier, C., Hannequin, D., Coutant, S., Rovelet-Lecrux, A., Wallon, D., Rousseau, S., et al. (2012). High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol. Psychiatry 17, 875-879. doi: 10.1038/mp.2012.15
98. Pugh, P. L., Vidgeon-Hart, M. P., Ashmeade, T., Culbert, A. A., Seymour, Z., Perren, M. J., et al. (2007). Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J. Neuroinflammation 4:8. doi: 10.1186/1742-2094-4-8
99. Puumala, T., Greijus, S., Narinen, K., Haapalinna, A., Riekkinen, P. Sr., and Sirvio, J. (1998). Stimulation of alpha-1 adrenergic receptors facilitates spatial learning in rats. Eur. Neuropsychopharmacol. 8, 17-26. doi: 10.1016/S0924-977X(97)00040-0
100. Puumala, T., Sirvio, J., Ruotsalainen, S., and Riekkinen, P. Sr. (1996). Effects of St-587 and prazosin on water maze and passive avoidance performance of scopolamine-treated rats. Pharmacol. Biochem. Behav. 55, 107-115. doi: 10.1016/0091-3057(95)02231-7
101. Qu, L. L., Guo, N. N., and Li, B. M. (2008). Beta1- and beta2-adrenoceptors in basolateral nucleus of amygdala and their roles in consolidation of fear memory in rats. Hippocampus 18, 1131-1139. doi: 10.1002/hipo.20478
102. Rajabi, S., Shamsizadeh, A., Amini, H., Shirazi, M., Allahtavakoli, M., Abbasnejad, M., et al. (2012). Effect of DSP-4 induced central noradrenergic depletion on tactile learning in rat. Neurol. Res. 34, 80-84. doi: 10.1179/1743132811Y.0000000050
103. Raskind, M. A., Peskind, E. R., Holmes, C., and Goldstein, D. S. (1999). Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol. Psychiatry 46, 756-765. doi: 10.1016/S0006-3223(99)00008-6
104. Reinikainen, K. J., Paljarvi, L., Huuskonen, M., Soininen, H., Laakso, M., and Riekkinen, P. J. (1988). A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J. Neurol. Sci. 84, 101-116. doi: 10.1016/0022-510X(88)90179-7
105. Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39, 168-177. doi: 10.1038/ng1943
106. Rosenberg, P. B., Mielke, M. M., Tschanz, J., Cook, L., Corcoran, C., Hayden, K. M., et al. (2008). Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am. J. Geriatr. Psychiatry 16, 883-892. doi: 10.1097/JGP.0b013e318181276a
107. Ruetti, E., Justel, N., Mustaca, A., and Boccia, M. (2014). Corticosterone and propranolol's role on taste recognition memory. Pharmacol. Biochem. Behav. 127, 37-41. doi: 10.1016/j.pbb.2014.09.013
108. Ruiz, J., Martin, I., Callado, L. F., Meana, J. J., Barturen, F., and Garcia-Sevilla, J. A. (1993). Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neurosci. Lett. 160, 109-112. doi: 10.1016/0304-3940(93)90925-B
109. Saber, A. J., and Cain, D. P. (2003). Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. Neuropsychopharmacology 28, 1247-1256. doi: 10.1038/sj.npp.1300163
110. Sadalge, A., Coughlin, L., Fu, H., Wang, B., Valladares, O., Valentino, R., et al. (2003). alpha 1d Adrenoceptor signaling is required for stimulus induced locomotor activity. Mol. Psychiatry 8, 664-672. doi: 10.1038/sj.mp.4001351
111. Salehi, A., Faizi, M., Colas, D., Valletta, J., Laguna, J., Takimoto-Kimura, R., et al. (2009). Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 1:7ra17. doi: 10.1126/scitranslmed.3000258
112. Sallee, F. R., and Pollock, B. G. (1990). Clinical pharmacokinetics of imipramine and desipramine. Clin. Pharmacokinet. 18, 346-364. doi: 10.2165/00003088-199018050-00002
113. Salm, A. K., and Mccarthy, K. D. (1989). Expression of beta-adrenergic receptors by astrocytes isolated from adult rat cortex. Glia 2, 346-352. doi: 10.1002/glia.440020507
114. Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., et al. (2004). Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol. 61, 1200-1205. doi: 10.1001/archneur.61.8.1200
115. Schubert, D. (2005). Glucose metabolism and Alzheimer's disease. Ageing Res. Rev. 4, 240-257. doi: 10.1016/j.arr.2005.02.003
116. Schutsky, K., Ouyang, M., and Thomas, S. A. (2011). Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled ß2-adrenergic signaling. Learn. Mem. 18, 598-604. doi: 10.1101/lm.2302811
117. Scullion, G. A., Kendall, D. A., Marsden, C. A., Sunter, D., and Pardon, M. C. (2011). Chronic treatment with the alpha2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPxPS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology 60, 223-234. doi: 10.1016/j.neuropharm.2010.09.002
118. Shankle, W. R., Nielson, K. A., and Cotman, C. W. (1995). Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis. Assoc. Disord. 9, 233-237. doi: 10.1097/00002093-199509040-00010
119. Shao, Y., and Sutin, J. (1992). Expression of adrenergic receptors in individual astrocytes and motor neurons isolated from the adult rat brain. Glia 6, 108-117. doi: 10.1002/glia.440060205
120. Shimohama, S., Taniguchi, T., Fujiwara, M., and Kameyama, M. (1986). Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J. Neurochem. 47, 1295-1301.
121. Sirviö, J., Riekkinen, P. Jr., Valjakka, A., Jolkkonen, J., and Riekkinen, P. J. (1991). The effects of noradrenergic neurotoxin, DSP-4, on the performance of young and aged rats in spatial navigation task. Brain Res. 563, 297-302. doi: 10.1016/0006-8993(91)91550-K
122. Sontag, T. A., Hauser, J., Kaunzinger, I., Gerlach, M., Tucha, O., and Lange, K. W. (2008). Effects of the noradrenergic neurotoxin DSP4 on spatial memory in the rat. J. Neural. Transm. 115, 299-303. doi: 10.1007/s00702-007-0830-5
123. Sparks, D. L., Dekosky, S. T., and Markesbery, W. R. (1988). Alzheimer's disease: aminergic-cholinergic alterations in hypothalamus. Arch. Neurol. (Chicago) 45, 994-999. doi: 10.1001/archneur.1988.00520330084014
124. Summers, W. K. (2006). The management of agitation in demented patients with propranolol. J. Alzheimers Dis. 9, 69-75.
125. Sutin, J., and Shao, Y. (1992). Resting and reactive astrocytes express adrenergic receptors in the adult rat brain. Brain Res. Bull. 29, 277-284. doi: 10.1016/0361-9230(92)90057-5
126. Swanson, L. W., and Hartman, B. K. (1975). The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J.Comp. Neurol. 163, 467-505. doi: 10.1002/cne.901630406
127. Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., and Raskind, M. A. (2006). Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 26, 467-478. doi: 10.1523/JNEUROSCI.4265-05.2006
128. Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., and Raskind, M. A. (2007). Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience 146, 471-480. doi: 10.1016/j.neuroscience.2007.01.031
129. Taherian, F., Vafaei, A. A., Vaezi, G. H., Eskandarian, S., Kashef, A., and Rashidy-Pour, A. (2014). Propranolol-induced impairment of contextual fear memory reconsolidation in rats: a similar effect on weak and strong recent and remote memories. Basic Clin. Neurosci. 5, 231-239.
130. Takahashi, J., Shibata, T., Sasaki, M., Kudo, M., Yanezawa, H., Obara, S., et al. (2015). Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: high-resolution fast spin-echo T1-weighted imaging. Geriatr. Gerontol. Int. 15, 334-340. doi: 10.1111/ggi.12280
131. Tanaka, K. F., Kashima, H., Suzuki, H., Ono, K., and Sawada, M. (2002). Existence of functional beta1- and beta2-adrenergic receptors on microglia. J. Neurosci. Res. 70, 232-237. doi: 10.1002/jnr.10399
132. Tejani-Butt, S. M., Yang, J., and Zaffar, H. (1993). Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease. Brain Res. 631, 147-150. doi: 10.1016/0006-8993(93)91201-3
133. Teri, L., Reifler, B. V., Veith, R. C., Barnes, R., White, E., Mclean, P., et al. (1991). Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J. Gerontol. 46, P372-P377. doi: 10.1093/geronj/46.6.P372
134. Thomas, S. A., and Palmiter, R. D. (1997). Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. Behav. Neurosci. 111, 579-589. doi: 10.1037/0735-7044.111.3.579
135. Tohgi, H., Ueno, M., Abe, T., Takahashi, S., and Nozaki, Y. (1992). Concentration of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J. Neural Transm. Park. Dis. Dement. Sect. 4, 69-77. doi: 10.1007/BF02257623
136. Torkaman-Boutorabi, A., Danyali, F., Oryan, S., Ebrahimi-Ghiri, M., and Zarrindast, M.-R. (2014). Hippocampal a-adrenoceptors involve in the effect of histamine on spatial learning. Physiol. Behav. 129, 17-24. doi: 10.1016/j.physbeh.2014.02.009
137. Tzavara, E. T., Bymaster, F. P., Overshiner, C. D., Davis, R. J., Perry, K. W., Wolff, M., et al. (2006). Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol. Psychiatry 11, 187-195. doi: 10.1038/sj.mp.4001763
138. Veyrac, A., Nguyen, V., Marien, M., Didier, A., and Jourdan, F. (2007). Noradrenergic control of odor recognition in a nonassociative olfactory learning task in the mouse. Learn. Mem. 14, 847-854. doi: 10.1101/lm.708807
139. Wang, D., Fu, Q., Zhou, Y., Xu, B., Shi, Q., Igwe, B., et al. (2013a). ß2 Adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. J. Biol. Chem. 288, 10298-10307. doi: 10.1074/jbc.M112.415141
140. Wang, J., Wright, H. M., Vempati, P., Li, H., Wangsa, J., Dzhuan, A., et al. (2013b). Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease. J. Alzheimers Dis. 33, 1147-1156. doi: 10.3233/JAD-2012-120904
141. Wang, L., Bodner, M., and Zhou, Y. D. (2013c). Distributed neural networks of tactile working memory. J. Physiol. Paris 107, 452-458. doi: 10.1016/j.jphysparis.2013.06.001
142. Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., Mcfall, Y. H., et al. (2009a). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am. J. Geriatr. Psychiatry 17, 744-751. doi: 10.1097/JGP.0b013e3181ab8c61
143. Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., et al. (2007). Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129, 397-410. doi: 10.1016/j.cell.2007.03.015
144. Wang, Q. W., Rowan, M. J., and Anwyl, R. (2009b). Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. Neurobiol. Aging 30, 1608-1613. doi: 10.1016/j.neurobiolaging.2007.12.004
145. Warner, T. A., and Drugan, R. C. (2012). Morris water maze performance deficit produced by intermittent swim stress is partially mediated by norepinephrine. Pharmacol. Biochem. Behav. 101, 24-34. doi: 10.1016/j.pbb.2011.11.009
146. Xiang, Y. K. (2011). Compartmentalization of beta-adrenergic signals in cardiomyocytes. Circ. Res. 109, 231-244. doi: 10.1161/CIRCRESAHA.110.231340
147. Yu, J. T., Tan, L., Ou, J. R., Zhu, J. X., Liu, K., Song, J. H., et al. (2008). Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. Brain Res. 1210, 216-222. doi: 10.1016/j.brainres.2008.03.019
148. Yu, N. N., Wang, X. X., Yu, J. T., Wang, N. D., Lu, R. C., Miao, D., et al. (2010). Blocking beta2-adrenergic receptor attenuates acute stress-induced amyloid beta peptides production. Brain Res. 1317, 305-310. doi: 10.1016/j.brainres.2009.12.087
149. Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341. doi: 10.1001/archneur.60.3.337
150. Zhou, H. C., Sun, Y. Y., Cai, W., He, X. T., Yi, F., Li, B. M., et al. (2013). Activation of beta2-adrenoceptor enhances synaptic potentiation and behavioral memory via cAMP-PKA signaling in the medial prefrontal cortex of rats. Learn. Mem. 20, 274-284. doi: 10.1101/lm.030411.113
151. Zoladz, P. R., Fleshner, M., and Diamond, D. M. (2013). Differential effectiveness of tianeptine, clonidine and amitriptyline in blocking traumatic memory expression, anxiety and hypertension in an animal model of PTSD. Prog. Neuropsychopharmacol. Biol. Psychiatry 44, 1-16. doi: 10.1016/j.pnpbp.2013.01.001